Showing results (561-570 of 579) with videos related to
Sort By:
Pageof 58
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|December 13, 2012
Clinical characteristics of patients with tuberculosis-destroyed lungC K Rhee, K H Yoo, J H Lee, et al.Environmental Research|October 10, 2023
Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodiesJames Hollister, Alberto J Caban-Martinez, Katherine D Ellingson, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 20, 2021
Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 InfectionHarmony L Tyner, Jefferey L Burgess, Lauren Grant, et al.The Journal of Infectious Diseases|November 12, 2024
Association of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential WorkersJosephine Mak, Sana Khan, Amadea Britton, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2024
Hybrid Immunity and SARS-CoV-2 Antibodies: Results of the HEROES-RECOVER Prospective Cohort StudyJames K Romine, Huashi Li, Melissa M Coughlin, et al.Diseases (Basel, Switzerland)|August 28, 2024
Evaluating Immunologic and Illness Outcomes of SARS-CoV-2 Infection in Vaccinated and Unvaccinated Children Aged ≥ 5 Years, in a Multisite Longitudinal CohortCynthia Porter, Zoe L Lyski, Jennifer L Uhrlaub, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 29, 2022
Severe Acute Respiratory Syndrome Coronavirus 2 Infection History and Antibody Response to 3 Coronavirus Disease 2019 Messenger RNA Vaccine DosesMeghan K Herring, James K Romine, Meredith G Wesley, et al.Journal of the Pediatric Infectious Diseases Society|December 10, 2024
Protection From COVID-19 Vaccination and Prior SARS-CoV-2 Infection Among Children Aged 6 Months-4 Years, United States, September 2022-April 2023Leora R Feldstein, Jasmine Ruffin, Ryan Wiegand, et al.JAMA|February 6, 2024
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 YearsLeora R Feldstein, Amadea Britton, Lauren Grant, et al.Journal for Immunotherapy of Cancer|April 8, 2025
Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitorsEileen L Chang, Renee Liu, Kiandokht Keyhanian, et al.Pageof 58